FLOT2

Across TCGA pan-cancer cohorts, FLOT2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FLOT2 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FLOT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FLOT2 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

LUAD, HNSC, and COAD are the cancer types where FLOT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.785	0.980	.001	63	view →
HNSC	DFS	Tertile	III,IV	0.380	1.000	.016	17	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
GBM	DFS	Tertile	All	0.893	0.746	.021	5	view →
PDAC	OS	Tertile	All	0.700	0.925	.007	5	view →
CCRCC	OS	Median	II,III,IV	1.000	0.449	.032	1	view →
LSCC	DFS	Quartile	All	0.728	0.876	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FLOT2–LUAD (DFS)

Open the LUAD breakdown →